Paklitaksel/Usnik Asit Kombinasyonunun Meme Kanseri Hücre Hatları Üzerine Etkisi
Dinçsoy, Adnan Berk
xmlui.mirage2.itemSummaryView.MetaDataShow full item record
Breast Cancer was the second common cancer worldwide in 2012. Using combination of multiple drugs for treatment has been proven to be more affective by research. Paclitaxel is a chemotherapy medication used to treat a number of types of cancer including breast and uterus cancers. Usnic acid’s antiproliferative and apoptosis inducing effects was shown on many research. In this study primarily the usnic acid on HCC38 human breast cancer and 4T1 mouse cancer cell line was assessed in vitro to show whether it had a cell viability reducing effect. Afterwards the effectiveness of the usage of the usnic acid and paclitaxel together on cell viability has been aimed to evaluate. On HCC38 cells as a result of application of 12.5 μM concentrations of usnic acid 48 hours and 72 hours, cell viability was in order decreased to 83% and 62%. The parameter’s according to the result of the MTT test with HCC38 cells show that the application of paclitaxel with usnic acid has cumulative effect on reducing the cell viability than individual application. As a result of flow cytometry analysis no significant difference was found on the mortality rate on the cell between the application of the combined usage and individual application of paclitaxel. As a result of application of usnic acid on 4T1 cells, cell viability deacreased but the decrease was not statistically significant. As a result of the MTT test with 4T1 cells the application of paclitaxel with usnic acid cell viability was decreased more than the individual application. According to the results of this study application of paclitaxel with usnic acid has a cumulative effect on reducing the cell viability.